242 related articles for article (PubMed ID: 26826441)
1. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
2. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
3. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
Biswas S; Sukla S; Field HJ
Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
[TBL] [Abstract][Full Text] [Related]
4. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
5. Helicase-primase as a target of new therapies for herpes simplex virus infections.
James SH; Larson KB; Acosta EP; Prichard MN
Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
[TBL] [Abstract][Full Text] [Related]
6. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
7. UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance.
Muylaert I; Zhao Z; Elias P
J Biol Chem; 2014 Nov; 289(47):32583-92. PubMed ID: 25278021
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
[TBL] [Abstract][Full Text] [Related]
9. HSV antivirals - current and future treatment options.
Birkmann A; Zimmermann H
Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
[TBL] [Abstract][Full Text] [Related]
10. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.
Sato Y; Suenaga T; Kobayashi M; Miyazaki N; Suzuki T; Ishioka K; Suzutani T
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0049421. PubMed ID: 34228537
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
13. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
14. UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients.
Labrunie T; Ducastelle S; Domenech C; Ader F; Morfin F; Frobert E
Antiviral Res; 2019 Aug; 168():114-120. PubMed ID: 31152759
[TBL] [Abstract][Full Text] [Related]
15. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
Biswas S; Field HJ
Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
[TBL] [Abstract][Full Text] [Related]
18. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
19. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
20. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir.
Pacreau ML; Bomme O; Burrel S; Boutolleau D
Antiviral Res; 2021 Nov; 195():105189. PubMed ID: 34666108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
